Low-dose radiation therapy is linked with improved progression-free survival in patients with advanced Hodgkin lymphoma (HL), according to a study involving 90 individuals. This is the case even in those who experience complete metabolic response after adriamycin, bleomycin, vinblastine, dacarbazine (ABVD). Participants had stage III-IV HL and were treated with either chemotherapy alone (n= 46) or combination therapy (n=44) between 1992 and 2012. Chemo regimen was mainly ABVD or a hybrid of it. Investigators looked at outcomes in those who achieved complete metabolic response. Among the results:
- 88% of patients receiving combo therapy experienced 5-year progression-free survival, vs 65% of those who were given chemo alone.
- Overall survival rates were 97% and 78%, respectively.
- Patients <45 years of age and those receiving combination regimens were more likely to experience improved progression-free survival.
- Secondary malignancies were similar in both groups.
- Cardiac events occurred a bit more often in patients receiving combo regimens.
Song E, Torok J, Wu Y, et al. Consolidation radiation therapy for advanced Hodgkin lymphoma in complete metabolic response by PET-CT or gallium. [Published online ahead of print December 29, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.12.007.
This Week's Must Reads
Must Reads in Hodgkin Lymphoma
Adding Bv improved survival for some Hodgkin patients, Evens AM et al. J Clin Oncol. 2018 Sep 4. doi: 10.1200/JCO.2018.79.0139.
Substantial late mortality risk persists after childhood BMT , Holmqvist AS et al. JAMA Oncol. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2453.
PET findings safely drive chemo decisions in Hodgkin lymphoma patients, Casasnovas O et al. ASCO 2018 (annual meeting of the American Society of Clinical Oncology), Abstract 7503.
Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.